{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:31Z","timestamp":1761920491776,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","award":["R431 \u2013 A29805"],"award-info":[{"award-number":["R431 \u2013 A29805"]}],"id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.msard.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:13:05Z","timestamp":1536635585000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clinical utility of anti-MOG antibody testing in a Danish cohort"],"prefix":"10.1016","volume":"26","author":[{"given":"Viktoria","family":"Papp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika R","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Blinkenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poul Erik Hyldgaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.09.010_bib0001","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.09.010_bib0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/WCO.0000000000000551","article-title":"Mechanisms for lesion localization in neuromyelitis optica spectrum disorders","volume":"31","author":"Bradl","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0003","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.010_bib0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/00365521.2015.1126855","article-title":"Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-Year follow-up","volume":"51","author":"Garcia-Medina","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.msard.2018.09.010_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2018.09.010_bib0007","first-page":"263","article-title":"Inflammatory demyelinating diseases of the central nervous system","volume":"145","author":"H\u00f6ftberger","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0008","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.09.010_bib0009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.09.010_bib0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.09.010_bib0011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis\u202f: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.09.010_bib0012","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2018.09.010_bib0013","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.09.010_bib0014","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.lpm.2016.11.020","article-title":"Optic neuritis associated to treatment with infliximab","volume":"46","author":"Landais","year":"2017","journal-title":"Presse Med."},{"key":"10.1016\/j.msard.2018.09.010_bib0015","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.09.010_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"dos Passos","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0017","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0018","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bjo.2006.111666","article-title":"The use of infliximab in ocular inflammation","volume":"92","author":"Prendiville","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.msard.2018.09.010_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.09.010_bib0020","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0021","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a french national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2018.09.010_bib0022","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00415-007-0730-5","article-title":"Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis","volume":"255","author":"Shimizu","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0023","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.09.010_bib0024","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.010_bib0026","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.09.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. NeuroInflammation"},{"key":"10.1016\/j.msard.2018.09.010_bib0028","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:28Z","timestamp":1761900088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":28,"alternative-id":["S2211034818303225"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.010","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of anti-MOG antibody testing in a Danish cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}